Regenxbio's GAAP loss for three months of 2021 was $50.139 million, up 25.2% from $40.038 million in the previous year. Revenue increased 7% to $18.884 million from $17.644 million a year earlier.
Regenxbio's GAAP loss for three months of 2021 was $50.139 million, up 25.2% from $40.038 million in the previous year. Revenue increased 7% to $18.884 million from $17.644 million a year earlier. 
regenxbio.gcs-web.com
English (US) 